PAREXEL PROMOTES DR. MARK A. GOLDBERG TO CHIEF OPERATING OFFICER
BOSTON, MA, July 16, 2008 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, announced today that it has promoted Mark A. Goldberg, M.D., to Chief Operating Officer (COO). Dr. Goldberg previously served as President of Clinical Research Services and Perceptive Informatics at PAREXEL. He will continue to oversee these areas of the Company and report to Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL.
“Dr. Goldberg has been an asset to PAREXEL’s executive management team for more than 11 years. His appointment as COO is in recognition of his strong leadership skills and increasing responsibilities, especially as we have expanded our clinical development capabilities and global footprint, including the recent extension of our capabilities in the Asia-Pacific region,” said Mr. von Rickenbach. “Dr. Goldberg has led the strong performance in Clinical Research Services, our largest business segment, and has helped to build Perceptive Informatics into a leading provider of advanced technologies that facilitate the clinical development process. We look forward to his continued contributions in meeting our operational and financial goals, and solidifying our position as a global leader in full service clinical development.”
Dr. Goldberg stated, “In this role, I look forward to working with our global management team to capitalize on the strong market opportunity for global biopharmaceutical services. My focus will include further strengthening our client relationships, as well as leveraging PAREXEL’s leadership role in the convergence of services and technology in support of clinical research.”
Dr. Goldberg’s combined medical, technical, and clinical research expertise has positioned him well to lead Clinical Research Services and Perceptive Informatics at PAREXEL. He joined PAREXEL in 1997, establishing the Company’s Medical Imaging Group to leverage imaging data as a surrogate end point, or biomarker, in evaluating the safety and efficacy of new products. In 2000, Dr. Goldberg was involved in establishing Perceptive Informatics to deliver advanced technology solutions that improve development and commercialization processes for the biopharmaceutical industry. Today, Perceptive Informatics has a portfolio of products and services including medical imaging, Interactive Voice and Web Response Systems, and the industry-leading IMPACT® Clinical Trial Management System (CTMS), which has approximately 26,000 users—the largest global CTMS user-base. In 2005, Dr. Goldberg took responsibility for the Clinical Research Services business and has achieved strong performance in new business wins, revenue growth, and profitability improvement. During this time, he continued to expand the offerings of the business, which provides capabilities across a broad range of therapeutic areas and all phases of clinical research.
Prior to joining PAREXEL, Dr. Goldberg served as President and Director of WorldCare, Inc., a tele-health spin-off from Massachusetts General Hospital (MGH), which he helped found. Dr. Goldberg holds a degree in Computer Science and Engineering from the Massachusetts Institute of Technology (M.I.T.), and an M.D. degree from the University of Massachusetts Medical School. He completed residency training in Diagnostic Radiology at MGH where he also served as Chief Resident. Dr. Goldberg was a staff radiologist at MGH and maintains an appointment as Consultant in Radiology.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.